Gamida Cell Ltd.
Healthcare · Biological Products, (No Diagnostic Substances) · L3 · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|
| Revenue | $1.8M | — | — | — |
| Operating income | −$73.0M | −$75.0M | −$87.2M | −$60.9M |
| Net income | −$63.0M | −$79.4M | −$89.8M | −$61.6M |
| Total assets | $102.2M | $124.8M | $148.8M | $158.3M |
| Total liabilities | $105.1M | $132.8M | — | — |
| Equity | −$2.9M | −$8.0M | $43.9M | $128.9M |
| EPS (diluted) | $0.57 | $1.24 | — | — |
| Shares out. | 81.5M | 60.0M | 60.0M | 59.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −4094.1%
- Net margin
- −3531.2%
- Return on equity
- 2136.2%
- Return on assets
- −61.6%
- Return on capital (ROCE)
- −94.9%
- Liabilities / assets
- 102.9%
- Debt / equity
- —
- Book value / share
- $-0.04
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -18.26distress
- Accruals / assets
- 15.8%high accruals
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 5 warning● 1 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
- Strong return on equity (>15%)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 16, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Wills Stephen TDirector | Jan 31, 2024 | Grant | 200,000 | $0.00 |
| Tomasello ShawnDirector | Jan 31, 2024 | Grant | 200,000 | $0.00 |
| Adams JulianDirector | Jan 31, 2024 | Grant | 200,000 | $0.00 |
| Simantov RonitOfficer — CMO & CHIEF SCIENTIFIC OFFICER | Jan 31, 2024 | Grant | 480,319 | $0.00 |
| Borrello Ivan M.Director | Jan 31, 2024 | Grant | 200,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Modified shareholder rights · Change in control · Director / officer change · Other material eventMay 24, 2024
- Bankruptcy or receivershipApr 22, 2024
- Entered a material agreement · Results of operations · Debt acceleration / triggering event · Costs from exit or disposal · Director / officer change · Other material eventMar 27, 2024
- Director / officer changeMar 15, 2024
- Other material eventJan 29, 2024
- Regulation FD disclosureJan 8, 2024
- Director / officer changeDec 18, 2023
- Delisting / listing-standard noticeNov 24, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GFORM 15-12GMay 24, 2024
- 8-KCURRENT REPORTMay 24, 2024
- 10-QQUARTERLY REPORTMay 23, 2024
- NT 10-QNOTIFICATION OF LATE FILINGMay 16, 2024
- EFFECTMay 13, 2024
- EFFECTMay 13, 2024
- EFFECTMay 13, 2024
- 8-K/AAMENDMENT NO. 4 TO FORM 8-KMay 10, 2024
- S-8 POSPOST-EFFECTIVE AMENDMENTS TO FORM S-8May 9, 2024
- S-8 POSPOST-EFFECTIVE AMENDMENTS TO FORM S-8May 9, 2024
- S-8 POSPOST-EFFECTIVE AMENDMENTS TO FORM S-8May 9, 2024
- POS AMPOST-EFFECTIVE AMENDMENTS TO FORM S-3May 9, 2024
- POS AMPOST-EFFECTIVE AMENDMENTS TO FORM S-3May 9, 2024
- POS AMPOST-EFFECTIVE AMENDMENTS TO FORM S-3May 9, 2024
- 25-NSEApr 25, 2024
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.